NASDAQ:TNGX

Tango Therapeutics - TNGX Stock Forecast, Price & News

$7.52

+0.12 (+1.62%)

(As of 12/8/2022 03:10 PM ET)

Add

Compare

Today's Range: $7.38
▼
$7.76
50-Day Range: $3.41
▼
$8.16
52-Week Range: $3.18
▼
$11.73

Volume: 2,756 shs
Average Volume: 211,482 shs
Market Capitalization: $663.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

Tango Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 179.3% Upside
$21.00 Price Target
Short Interest: Bearish
2.86% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$1.20 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.26) to ($1.64) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.76 out of 5 stars

Medical Sector

817th out of 1,022 stocks

Pharmaceutical Preparations Industry

401st out of 499 stocks

3.5

Analyst's Opinion

Consensus Rating
Tango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.00, Tango Therapeutics has a forecasted upside of 179.3% from its current price of $7.52.
Amount of Analyst Coverage
Tango Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.86% of the float of Tango Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Tango Therapeutics has a short interest ratio ("days to cover") of 6.1.
Change versus previous month
Short interest in Tango Therapeutics has recently increased by 3.20%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Tango Therapeutics does not currently pay a dividend.
Dividend Growth
Tango Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TNGX.

0.0

News and Social Media Coverage

MarketBeat Follows
Only 1 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tango Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,202,524.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 3.70% of the stock of Tango Therapeutics is held by insiders.
Percentage Held by Institutions
80.02% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.26) to ($1.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tango Therapeutics is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tango Therapeutics is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tango Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TNGX Stock News Headlines

November 10, 2022 | msn.com

Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates

November 10, 2022 | finance.yahoo.com

Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights

November 1, 2022 | msn.com

Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

October 21, 2022 | msn.com

Why Tango Therapeutics Shares Rose 39.7% This Week

October 19, 2022 | finance.yahoo.com

Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 5, 2022 | finance.yahoo.com

Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting

September 26, 2022 | finance.yahoo.com

The past year for Tango Therapeutics (NASDAQ:TNGX) investors has not been profitable

September 6, 2022 | finance.yahoo.com

Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

August 16, 2022 | finance.yahoo.com

Can Tango Therapeutics, Inc. (TNGX) Climb 219% to Reach the Level Wall Street Analysts Expect?

August 14, 2022 | seekingalpha.com

Tango Therapeutics (TNGX) Investor Presentation - Slideshow

August 13, 2022 | finance.yahoo.com

The Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

August 10, 2022 | finance.yahoo.com

Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

August 2, 2022 | finance.yahoo.com

Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

June 27, 2022 | seekingalpha.com

Tango Therapeutics enters Russell 2000, Russell 3000 and Russell Microcap indexes

June 27, 2022 | finance.yahoo.com

Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

June 20, 2022 | finance.yahoo.com

We Think Tango Therapeutics (NASDAQ:TNGX) Can Afford To Drive Business Growth

June 15, 2022 | benzinga.com

Tango Therapeutics's Return On Capital Employed Insights

May 11, 2022 | finance.yahoo.com

Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

May 9, 2022 | finance.yahoo.com

Tango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022

April 22, 2022 | msn.com

Wall Street Analysts Predict a 176% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should Know

April 19, 2022 | finance.yahoo.com

Shareholders in Tango Therapeutics (NASDAQ:TNGX) are in the red if they invested a year ago

March 28, 2022 | seekingalpha.com

Tango Therapeutics GAAP EPS of -$0.25 in-line, revenue of $5.72M misses by $1.01M

March 28, 2022 | finance.yahoo.com

Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

March 8, 2022 | finance.yahoo.com

Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting

March 6, 2022 | investing.com

Tango Therapeutics Inc (TNGX)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TNGX Company Calendar

Today: 12/08/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/27/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TNGX
CUSIP: N/A
CIK: 1819133
Web: www.tangotx.com
Phone: 857-320-4900
Fax: N/A
Employees: 91
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $21.00
High Stock Price Forecast: $21.00
Low Stock Price Forecast: $21.00
Forecasted Upside/Downside: +179.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,240,000.00
Net Margins: -418.63%
Pretax Margin: -417.89%
Return on Equity: -32.72%
Return on Assets: -21.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.83
Quick Ratio: 7.83

Sales & Book Value

Annual Sales: $37.04 million
Price / Sales: 17.90
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.94 per share
Price / Book: 1.91

Miscellaneous

Outstanding Shares: 88,180,000
Free Float: 84,914,000
Market Cap: $663.11 million
Optionable: Not Optionable
Beta: 1.85

Key Executives

Dr. Barbara L. Weber M.D. (Age 66)
Pres, CEO & Director
Comp: $796.2k

Ms. Daniella Beckman CPA (Age 43)
Chief Financial Officer
Comp: $545.82k

Dr. Alan Huang Ph.D. (Age 49)
Chief Scientific Officer
Comp: $566.54k

Dr. Alan Ashworth FRS (Age 61)
Ph.D., Founder & Member of Scientific Advisory Board

Dr. Levi Garraway M.D.
Ph.D., Founder

Dr. William G. Kaelin Jr. (Age 64)
M.D., Founder & Member of Scientific Advisory Board

Dr. Timothy K. Lu M.D. (Age 41)
Ph.D., Founder

Dr. Antoni Ribas M.D. (Age 55)
Ph.D., Founder & Member of Scientific Advisory Board

Mr. Douglas J. Barry Esq. (Age 52)
J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec.

Mr. John C. Ross M.S.
VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TNGX Stock - Frequently Asked Questions

Should I buy or sell Tango Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNGX shares.
View TNGX analyst ratings or view top-rated stocks.
What is Tango Therapeutics' stock price forecast for 2023?: 1 analysts have issued 12 month price objectives for Tango Therapeutics' shares. Their TNGX share price forecasts range from $21.00 to $21.00. On average, they expect the company's share price to reach $21.00 in the next year. This suggests a possible upside of 179.3% from the stock's current price.
View analysts price targets for TNGX or view top-rated stocks among Wall Street analysts.
How have TNGX shares performed in 2022?: Tango Therapeutics' stock was trading at $10.94 at the beginning of 2022. Since then, TNGX stock has decreased by 31.3% and is now trading at $7.52.
View the best growth stocks for 2022 here.
When is Tango Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our TNGX earnings forecast.

What is Tango Therapeutics' stock symbol?: Tango Therapeutics trades on the NASDAQ under the ticker symbol "TNGX."
Who are Tango Therapeutics' major shareholders?: Tango Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include EcoR1 Capital LLC (4.76%), Cormorant Asset Management LP (4.68%), BlackRock Inc. (3.31%), Vanguard Group Inc. (2.95%), State Street Corp (0.99%) and Citadel Advisors LLC (0.54%).
View institutional ownership trends.
How do I buy shares of Tango Therapeutics?: Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Tango Therapeutics' stock price today?: One share of TNGX stock can currently be purchased for approximately $7.52.
How much money does Tango Therapeutics make?: Tango Therapeutics (NASDAQ:TNGX) has a market capitalization of $663.11 million and generates $37.04 million in revenue each year. The company earns $-58,240,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.
How can I contact Tango Therapeutics?: Tango Therapeutics' mailing address is 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.tangotx.com. The company can be reached via phone at 857-320-4900.

This page (NASDAQ:TNGX) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial